Just three months after emerging with a $245m funding round, Aiolos Bio has been snapped up by GSK plc for four times that figure. The UK major gets its hands on AIO-001, an antibody with the same mechanism as AstraZeneca PLC and Amgen, Inc.’s asthma medicine Tezspire (tezepelumab).
GSK Takes A Deep Breath And Drops $1bn On Aiolos
The UK firm is following in AstraZeneca’s footsteps in doing a deal for an anti-TSLP antibody, though it remains some way behind its rival.
